Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Yezi Zhu"'
Publikováno v:
Asian Journal of Urology, Vol 7, Iss 3, Pp 251-257 (2020)
Aberrant activation of androgen receptor (AR) signaling occurs in patients treated with AR-targeted therapies, contributing to the development of castration-resistant prostate cancer (CRPC) and therapeutic resistance. Over the past decade, many AR va
Externí odkaz:
https://doaj.org/article/969d092d3d0e4c10899831222cfd6992
Autor:
Keliang Wang, Jie Luo, Shuyuan Yeh, Bosen You, Jialin Meng, Philip Chang, Yuanjie Niu, Gonghui Li, Changxue Lu, Yezi Zhu, Emmanuel S. Antonarakis, Jun Luo, Chi-Ping Huang, Wanhai Xu, Chawnshang Chang
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Castration resistant prostate cancer patients treated with enzalutamide may develop resistance to the drug. Here, the authors report that monoamine oxidase-A expression is increased in these resistant tumors and that the antidepressants phenelzine/cl
Externí odkaz:
https://doaj.org/article/e9d6def113e84a60bc881fcbffc3cdfb
Publikováno v:
Asian Journal of Urology, Vol 6, Iss 1, Pp 109-113 (2019)
Objective: Small cell prostate carcinoma (SCPC) is a rare and highly malignant subtype of prostate cancer. SCPC frequently lacks androgen receptor (AR) and prostate-specific antigen (PSA) expression, and often responds poorly to androgen deprivation
Externí odkaz:
https://doaj.org/article/4933bbdbb564424abf68ea09eb9962ab
Publikováno v:
Nanoscale Research Letters, Vol 13, Iss 1, Pp 1-8 (2018)
Abstract Nanomaterials were widely used as efficient adsorbents for environmental remediation of tetracycline pollution. However, the separation of the adsorbents posed the challenge to their practical applications. In this study, we grew magnetic Mn
Externí odkaz:
https://doaj.org/article/dcf9460d19e3431ba9c8991732c2f56d
Autor:
W. Nathaniel Brennen, Yezi Zhu, Ilsa M. Coleman, Susan L. Dalrymple, Lizamma Antony, Radhika A. Patel, Brian Hanratty, Roshan Chikarmane, Alan K. Meeker, S. Lilly Zheng, Jody E. Hooper, Jun Luo, Angelo M. De Marzo, Eva Corey, Jianfeng Xu, Srinivasan Yegnasubramanian, Michael C. Haffner, Peter S. Nelson, William G. Nelson, William B. Isaacs, John T. Isaacs
Publikováno v:
JCI Insight, Vol 6, Iss 8 (2021)
Resistance to AR signaling inhibitors (ARSis) in a subset of metastatic castration-resistant prostate cancers (mCRPCs) occurs with the emergence of AR– neuroendocrine prostate cancer (NEPC) coupled with mutations/deletions in PTEN, TP53, and RB1 an
Externí odkaz:
https://doaj.org/article/f6df29103c0e46759e5821f89b231584
Autor:
Nagalakshmi Nadiminty, Ramakumar Tummala, Wei Lou, Yezi Zhu, Xu-Bao Shi, June X Zou, Hongwu Chen, Jin Zhang, Xinbin Chen, Jun Luo, Ralph W deVere White, Hsing-Jien Kung, Christopher P Evans, Allen C Gao
Publikováno v:
PLoS ONE, Vol 7, Iss 3, p e32832 (2012)
Prostate cancer (PCa) is characterized by deregulated expression of several tumor suppressor or oncogenic miRNAs. The objective of this study was the identification and characterization of miR-let-7c as a potential tumor suppressor in PCa.Levels of e
Externí odkaz:
https://doaj.org/article/9a02ec23e9174007b2847f00a64e2340
Autor:
Allen C. Gao, Christopher P. Evans, Ramakumar Tummala, Wei Lou, Nagalakshmi Nadiminty, Chengfei Liu, Yezi Zhu
Docetaxel is the first-line standard treatment for castration-resistant prostate cancer. However, relapse eventually occurs due to the development of resistance to docetaxel. To unravel the mechanism of acquired docetaxel resistance, we established d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::014b08061baa4b9dd802c3f88c540ac3
https://doi.org/10.1158/1535-7163.c.6536403.v1
https://doi.org/10.1158/1535-7163.c.6536403.v1
Autor:
Susan L. Dalrymple, Yezi Zhu, Peter S. Nelson, Jun Luo, Jianfeng Xu, Alan K. Meeker, Samuel R. Denmeade, Emmanuel S. Antonarakis, S. Lilly Zheng, William B. Isaacs, Angelo M. De Marzo, Jody E. Hooper, Ilsa Coleman, John T. Isaacs, W. Nathaniel Brennen
Publikováno v:
Oncogene
The role of truncated androgen receptor splice variant-7 (AR-V7) in prostate cancer biology is an unresolved question. Is it simply a marker of resistance to 2nd-generation androgen receptor signaling inhibitors (ARSi) like abiraterone acetate (Abi)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3571a984b57691572f6678e3f0d4d0d6
https://doi.org/10.1038/s41388-020-01479-6
https://doi.org/10.1038/s41388-020-01479-6
Publikováno v:
Asian Journal of Urology
Asian Journal of Urology, Vol 7, Iss 3, Pp 251-257 (2020)
Asian Journal of Urology, Vol 7, Iss 3, Pp 251-257 (2020)
Aberrant activation of androgen receptor (AR) signaling occurs in patients treated with AR-targeted therapies, contributing to the development of castration-resistant prostate cancer (CRPC) and therapeutic resistance. Over the past decade, many AR va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d824da60e3885f5814b76e5e5e42d2f
https://doi.org/10.1016/j.ajur.2020.01.001
https://doi.org/10.1016/j.ajur.2020.01.001
Autor:
Jody E. Hooper, Susan L. Dalrymple, Samuel R. Denmeade, Yezi Zhu, Angelo M. De Marzo, W. Nathaniel Brennen, S. Lilly Zheng, Peter S. Nelson, Ilsa Coleman, John T. Isaacs, Jun Luo, Alan K. Meeker, Jianfeng Xu, Emmanuel S. Antonarakis, William B. Isaacs
Publikováno v:
Oncogene. 40:3914-3916
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e737885d05e6bce87383b260868b8a50
https://doi.org/10.1038/s41388-021-01805-6
https://doi.org/10.1038/s41388-021-01805-6